Selective serotonin 5-HT1B/1D receptor agonist; structurally derived from tryptamine. Prepn: R. Baker et al., EP 497512; eidem, US 5298520 (1992, 1994 both to Merck Sharp & Dohme); and binding characteristics: L. J. Street et al., J. Med. Chem. 38, 1799 (1995). Synthesis: C. Chen et al., Tetrahedron Lett. 35, 6981 (1994). Clinical pharmacokinetics: H. Cheng et al., Biopharm. Drug Dispos. 17, 17 (1996). LC-MS determn in plasma: D. A. McLoughlin et al., J. Chromatogr. A 726, 115 (1996). Comparative clinical trial in treatment of migraine: J. U. Adelman et al., Neurology 57, 1377 (2001). Review of pharmacology and therapeutic efficacy: K. Wellington, G. L. Plosker, Drugs 62, 1539-1574 (2002); of development and clinical experience: A. V. Krymchantowski, M. E. Bigal, Expert Rev. Neurother. 5, 597-603 (2005).
Crystal structure: K. Ravikumar et al., Acta Crystallogr. E63, 1958 (2007).
Antimigraine.
Antimigraine; Serotonin Receptor Agonist